Austrian Hypertrophic Cardiomyopathy Registry
ConditionHypertrophic Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Graz
About this trial
The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures
Disqualifiers
Age < 18 years
Known cardiac amyloidosis
Trial population
The study population includes subjects who fulfill criteria of HCM and are treated in Austria.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
All cause mortality
All cause mortality
Time frame
Through study completion, on average 20 years2
Cardiovascular events
Cardiovascular events
Time frame
Through study completion, on average 20 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov